HLS Therapeutics Inc.

C$4.41As of Sun 8 Nov 2026, 12:00 UTC
TSX:HLSHealthcare
Country Canada
PE (Fwd) •••
TSR 9Y CAGR (9.96%)
Div yield —
ROE (14.07%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.71
PE TTM —
TSR TTM (20.97%)
Mkt cap C$134.2M
ROIC (2.57%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$5.07
14.98%
(70.79%)
Hold 8|3|2|6|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.05
0.05
0.05
0.05
(3.63%)
0.62%
2.58%
5.02%
Revenue$M
7.528
7.361
7.495
7.888
10.56%
9.41%
7.18%
8.97%
Peers (US$95.02M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
5.100
4.973
5.182
EBIT/Intx
2.316
3.027
2.908
Own earn%
84.38
(25.27)
(24.68)
Sh yield%
15.81
17.98
19.32
Owners
Insiders/Inst%
4.90
77.77
Short interest%
2.15
SBC / revenue%
0.27
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
1
Op margin range%
15–19
$1 testx
—
Incr. ROIC%
4